We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lombard Med.Tec | LSE:LMT | London | Ordinary Share | GB00B7FT8W85 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 188.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/1/2011 10:55 | quite a decent volume on friday. let's see what this week brings. | nod | |
21/1/2011 16:22 | buys, sells, same thing just at different prices. no! | webshares | |
21/1/2011 16:21 | restassured the 2x 2mill plus trades are not simple (in my humble opinion) buys, I have no idea what they are but I do suspect they are roll overs but why that price beats me. I am sure someone more intelligent will give better opinion, | stable | |
21/1/2011 16:04 | next leg up perhaps. | webshares | |
21/1/2011 16:02 | Nice buy for over 2 million 3p on the way | restassured | |
19/1/2011 18:37 | nod. i think your right. 1 or 2 II's getting involved. probably just under 3% a piece. so no declaring. | webshares | |
19/1/2011 13:56 | RNS Number:5571 Lombard Medical Technologies PLC 13 December 2005 Lombard Medical Technologies PLC commences trading on AIM London, UK, 13 December 2005: Lombard Medical Technologies PLC ("Lombard" or the "Company"), a developer of stent grafts and other medical products, announces that trading will commence today on the AIM market of the London Stock Exchange at 8:00am under the ticker symbol LMT. The nominated adviser and broker to the Company and agent in relation to the placing is Code Securities Limited. The commencement of trading follows the placing of 16,466,359 new Ordinary Shares at 159 pence per Ordinary Share, raising gross proceeds for the Company of #26.2 million (#23.9 million, net of expenses). A total of 48,893,590 Ordinary Shares will be in issue on admission, giving a market capitalisation immediately following admission of #77.7 million. Alistair Taylor, Executive Chairman of Lombard, commented: "We are very pleased to have completed our IPO on AIM. With the proceeds from the flotation, we now look forward to commencing final pivotal clinical trials of our AorfixTM stent graft in the key US market, for which conditional approval has been given by the FDA." At around 45x dilution 6years of trials/approvals later this share must be worth 3p ??? | richi4 | |
18/1/2011 23:45 | Stable, interesting With the sudden drop in volume you have to wonder whether the recent big trades were down to just one or two players/investors. With over 2 billion shares in issue - 1% would be 20 million shares. There has been no RNS about holdings. | nod | |
18/1/2011 21:13 | Stable - a fair rant. the market is rife with this sort of behavior. i'm glad to be on the right side of it though. but we'll see what happens...2011 could be LMT's year | webshares | |
18/1/2011 21:10 | Thanks for analysis. There has certainly been consistently very large volume. Someone, somewhere is interested. May take time, but this is different to 2010. | bbluesky | |
18/1/2011 19:35 | at first glance today's trading does not look very positive with the trades showing a large pc of sells.Volume was low If you are able to look at the mm and brokers other place, the Plus market. Volume was 1.4 million and nearly all were buys(although plus shows them as sales, It is days like today where all sales are put on the main market and buys hidden on plus which exposes the mm and brokers for the devious so and sos they can be. They show bid offer prices outside those on the main markets so that buys can look like sales and vice versa, anything to give a false impression end of rant | stable | |
18/1/2011 08:34 | bit of resistance here but good consolidation as it did at 1.6. then maybe the next leg up.... need news | webshares | |
17/1/2011 21:34 | I'm sure all LMT investors are betting on the day when the bid comes in. Great trading volume day after day. | nod | |
17/1/2011 13:22 | it's all go in the medical market. Smiths Group headed up the risers board with an 8% surge, ahead 106p to 1388p, following Friday's after-close announcement that the firm had rejected a £2.45 billion cash approach for its medical arm. Smith & Nephew followed it with a further 4% gain, up 27p to 712p, after weekend reports that US suitor Johnson & Johnson is preparing to make a formal offer for the group worth £7 billion | johnyee 7 | |
17/1/2011 07:06 | me too percentage wise :) | munkychunky | |
16/1/2011 19:53 | me to rayrac. not boasting just happy and not selling nay time soon | webshares | |
15/1/2011 11:18 | I'm sitting on hefty profits here. Just thought I would let you know, helps build confidence among followers? | rayrac | |
14/1/2011 21:03 | yes, good volumes each day and steady move up. some quite large sells i see but they are being mopped up. This would be a great time to release a bit of extra news... | nod | |
14/1/2011 16:55 | lovely. good volume we'll break 2p next week | webshares | |
14/1/2011 11:11 | web looks like onwards and upwards..;-) | jab118 | |
13/1/2011 16:48 | fully expected a pullback today but happy only a small retrace. where next. back to 1.6 or onwards and upwards?? | webshares | |
13/1/2011 11:47 | thank you - that's encouraging :) | nod | |
13/1/2011 11:43 | Generally a PMA will take up to 180 days to get FDA approval. However, as the submission is in modules, and assuming these are approved module by module, the general response time for PMA updates is up to 60 days post submission. | roundyg | |
13/1/2011 11:31 | i can't recall where i read it (perhaps on this BB) but i thought we were looking for fda approval around 6 months after the clinical data is filed. perhaps someone could clarify this. | nod | |
13/1/2011 08:34 | they are going to submit the final data to the fda in America in the first half of this year,does that mean they could get approval in the first half as well? | johnyee 7 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions